(Q35664627)

9 August 2017

1 reference

title

Aromatase inhibitors in malignant diseases of aging (English)

1 reference

9 August 2017

2

Lønning PE

1 reference

9 August 2017

Johannessen DC

1

1 reference

9 August 2017

1 November 1992

1 reference

9 August 2017

1 reference

9 August 2017

2

1 reference

9 August 2017

6

1 reference

9 August 2017

530-545

1 reference

https://scigraph.springernature.com/pub.10.2165/00002512-199202060-00008

9 August 2017

0 references

cites work

Treatment of metastatic breast cancer with aminoglutethimide

1 reference

12 December 2020

Estrone and estradiol content in human breast tumors: Relationship to estradiol receptors

1 reference

12 December 2020

Influence of aminoglutethimide on the metabolism of medroxyprogesterone acetate and megestrol acetate in postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

The effect of the aromatase inhibitor, 4-(phenylthio)-4-androstene-3,17-dione, on dimethylbenz(A)anthracene-induced rat mammary tumors

1 reference

12 December 2020

1 reference

12 December 2020

Plasma Precursors of Estrogen. II. Correlation of the Extent of Conversion of Plasma Androstenedione to Estrone with Age1

1 reference

12 December 2020

Aminoglutethimide Inhibits Extraglandular Estrogen Production in Postmenopausal Women with Breast Carcinoma*

1 reference

12 December 2020

Aminoglutethimide and advanced breast cancer [proceedings]

1 reference

12 December 2020

Impact of Continuously Administered Catechol Estrogens on Uterine Growth and Luteinizing Hormone Secretion*

1 reference

12 December 2020

Metabolism of estrogens—natural and synthetic

1 reference

12 December 2020

Use of aminoglutethimide as second-line endocrine therapy in metastatic breast cancer

1 reference

12 December 2020

Aromatization of androstenedione by cultured human fibroblasts

1 reference

12 December 2020

Aminoglutethimide (Elipten-Ciba) as an inhibitor of adrenal steroidogenesis: mechanism of action and therapeutic trial.

1 reference

12 December 2020

Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide

1 reference

12 December 2020

Estrogen and progesterone receptors in bronchogenic carcinoma

1 reference

12 December 2020

Aminoglutethimide: medical adrenalectomy in the management of carcinoma of the prostate. A review after 6 years

1 reference

12 December 2020

Aminoglutethimide therapy in breast cancer: relationship of blood levels to drug-related side effects

1 reference

12 December 2020

Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide

1 reference

12 December 2020

Preservation of androgen secretion during estrogen suppression with aminoglutethimide in the treatment of metastatic breast carcinoma

1 reference

12 December 2020

Megestrol acetate versus aminoglutethimide for metastatic breast cancer

1 reference

12 December 2020

Treatment of breast carcinoma with aminoglutethimide.

1 reference

12 December 2020

Bilateral adrenalectomy in the treatment of cancer of the breast.

1 reference

12 December 2020

Lack of evidence for aromatase in human prostatic tissues: effects of 4-hydroxyandrostenedione and other inhibitors on androgen metabolism

1 reference

12 December 2020

Nuclei of stroma: site of highest estrogen concentration in human benign prostatic hyperplasia

1 reference

12 December 2020

Medical and surgical adrenalectomy in patients with advanced breast carcinoma

1 reference

12 December 2020

A phase I trial of CGS 16949A. A new aromatase inhibitor

1 reference

12 December 2020

Origin of serum estradiol in postmenopausal women

1 reference

12 December 2020

Aminoglutethimide in the treatment of metastatic breast cancer

1 reference

12 December 2020

Estrogens and benign prostatic hyperplasia: the basis for aromatase inhibitor therapy

1 reference

12 December 2020

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

1 reference

12 December 2020

Treatment of advanced breast cancer with aminoglutethimide: a 14-year experience

1 reference

12 December 2020

Estrone sulfate: a potential source of estradiol in human breast cancer tissues

1 reference

12 December 2020

Comparison of the pharmacokinetics and pharmacodynamics of unformulated and formulated 4-hydroxyandrostenedione taken orally by healthy men

1 reference

12 December 2020

Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer

1 reference

12 December 2020

Aminoglutethimide without hydrocortisone in the treatment of postmenopausal patients with advanced breast cancer.

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer

1 reference

12 December 2020

A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer

1 reference

12 December 2020

Aminoglutethimide after tamoxifen therapy in advanced breast cancer: M. D. Anderson Hospital experience.

1 reference

12 December 2020

4-Hydroxyandrostenedione in treatment of postmenopausal patients with advanced breast cancer

1 reference

12 December 2020

Aromatase inhibition in advanced prostatic cancer: preliminary communication.

1 reference

12 December 2020

Reduction of serum testosterone levels during chronic glucocorticoid therapy.

1 reference

12 December 2020

Suppression of residual oestrogen production with aminoglutethimide in women following surgical hypophysectomy or adrenalectomy.

1 reference

12 December 2020

A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients

1 reference

12 December 2020

Phase II study of aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer

1 reference

12 December 2020

Aminoglutethimide (with hydrocortisone) induced agranulocytosis in primary breast cancer

1 reference

12 December 2020

Source of Estrogen Production in Postmenopausal Women1

1 reference

12 December 2020

Aminoglutethimide therapy for advanced carcinoma of the prostate

1 reference

12 December 2020

Testosterone secretion and metabolism in male senescence

1 reference

12 December 2020

Comparison of Estramustine Phosphate, Methotrexate and cis-Platinum: in Patients with Advanced1 Hormone Refractory Prostate Cancer

1 reference

12 December 2020

Changes in the pituitary-testicular system with age.

1 reference

12 December 2020

Nuclear binding and retention of the receptor estrogen complex: relation to the agonistic and antagonistic properties of estriol

1 reference

12 December 2020

Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.

1 reference

12 December 2020

Preliminary trial of aminoglutethimide in breast cancer

1 reference

12 December 2020

Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide

1 reference

12 December 2020

The role of tissue steroids in regulating aromatase and oestradiol 17 beta-hydroxysteroid dehydrogenase activities in breast and endometrial cancer

1 reference

12 December 2020

Clinical and biochemical effect of aminoglutethimide in the treatment of advanced prostatic carcinoma

1 reference

12 December 2020

Evaluation of aminoglutethimide in stage D prostate cancer: an assessment of efficacy and toxicity in patients with tumors refractory to hormonal therapy

1 reference

12 December 2020

Adrenal androgen blockade in relapsed prostate cancer

1 reference

12 December 2020

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients

1 reference

12 December 2020

Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism

1 reference

12 December 2020

Aminoglutethimide as second-line endocrine treatment in metastatic breast cancer

1 reference

12 December 2020

Proceedings: The natural history of prostatic cancer

1 reference

12 December 2020

Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer

1 reference

12 December 2020

Studies on prostatic cancer: I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Treatment of advanced prostatic cancer, resistant to conventional therapy, with aminoglutethimide

1 reference

12 December 2020

Aminoglutethimide as second line therapy in advanced breast cancer

1 reference

12 December 2020

Inhibition of aromatase with CGS 16949A in postmenopausal women

1 reference

12 December 2020

The Hormonal Activity of the Postmenopausal Ovary

1 reference

12 December 2020

Irreversible thrombocytopenia following aminoglutethimide.

1 reference

12 December 2020

Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

1 reference

12 December 2020

Antitumor effect of a specific aromatase inhibitor, 1-methyl-androsta-1,4-diene-3,17-dione (atamestane), in female rats bearing DMBA-induced mammary tumors

1 reference

12 December 2020

Tamoxifen versus aminoglutethimide in advanced breast carcinoma: a randomized cross-over trial

1 reference

12 December 2020

Preliminary study of the treatment of advanced breast cancer in postmenopausal women with the aromatase inhibitor CGS 16949A

1 reference

12 December 2020

Studies on the mechanism of estrogen biosynthesis. 8. The development of inhibitors of the enzyme system in human placenta

1 reference

12 December 2020

Cross-over comparison of tamoxifen and aminoglutethimide in advanced breast cancer

1 reference

12 December 2020

Estrone sulfate and dehydroepiandrosterone sulfate concentrations in normal subjects and men with cirrhosis

1 reference

12 December 2020

Suppression of plasma 6-keto-prostaglandin F1 alpha and 13,14-dihydro-15-keto-prostaglandin F2 alpha by aminoglutethimide in advanced breast cancer

1 reference

12 December 2020

In vitro and in vivo studies demonstrating potent and selective estrogen inhibition with the nonsteroidal aromatase inhibitor CGS 16949A.

1 reference

12 December 2020

Commentary: a physiological approach to hepatic drug clearance

1 reference

12 December 2020

Oestrogen receptor proteins in malignant and fetal pancreas

1 reference

12 December 2020

Treatment of advanced postmenopausal breast cancer with an aromatase inhibitor, 4-hydroxyandrostenedione: phase II report

1 reference

12 December 2020

Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer

1 reference

12 December 2020

A dose response evaluation of delta-1-testololactone in advanced breast cancer.

1 reference

12 December 2020

Bilateral adrenalectomy for advanced prostatic carcinoma

1 reference

12 December 2020

Aromatase inhibition with 4-hydroxyandrostenedione in the treatment of postmenopausal patients with advanced breast cancer: a phase II study

1 reference

12 December 2020

Marked heterogeneity of aromatase activity in human malignant melanoma tissue

1 reference

12 December 2020

Low-dose aminoglutethimide in treatment of advanced breast cancer

1 reference

12 December 2020

Tamoxifen and aminoglutethimide in the management of patients with advanced endometrial carcinoma not responsive to medroxyprogesterone

1 reference

12 December 2020

Aminoglutethimide as treatment of postmenopausal women with advanced breast carcinoma

1 reference

12 December 2020

Increased estrogen-16α-hydroxylase activity in women with breast and endometrial cancer

1 reference

12 December 2020

Characterization and Comparison of Receptors for 17β-Estradiol and Progesterone in Human Proliferative Endometrium and Endometrial Carcinoma

1 reference

12 December 2020

Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer

1 reference

12 December 2020

Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer

1 reference

12 December 2020

Adrenal suppression in the treatment of carcinoma of the prostate

1 reference

12 December 2020

Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue

1 reference

12 December 2020

Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day

1 reference

12 December 2020

CGS 16949A, a new aromatase inhibitor in the treatment of breast cancer--a phase I study

1 reference

12 December 2020

Aminoglutethimide in patients with metastatic breast cancer

1 reference

12 December 2020

Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings

1 reference

12 December 2020

Systemic lupus erythematosus induced by aminoglutethimide

1 reference

12 December 2020

Oral 4-hydroxyandrostenedione, a new endocrine treatment for disseminated breast cancer

1 reference

12 December 2020

Estrogen and progesterone receptors in meningiomas: comparison of nuclear binding, dextran-coated charcoal, and immunoperoxidase staining assays.

1 reference

12 December 2020

Randomized trial comparing aminoglutethimide with high-dose medroxyprogesterone acetate in therapy for advanced breast carcinoma.

1 reference

12 December 2020

Aromatase, 17 beta-hydroxysteroid dehydrogenase and intratissular sex hormone concentrations in cancerous and normal glandular breast tissue in postmenopausal women

1 reference

12 December 2020

A clinical trial of aminoglutethimide in advanced postmenopausal breast carcinoma: low response in patients previously treated with medroxyprogesterone

1 reference

12 December 2020

Clinical effect of aminoglutethimide, medical adrenalectomy, in treatment of 43 patients with advanced prostatic carcinoma

1 reference

12 December 2020

The effects of aminoglutethimide and hydrocortisone, alone and combined, on androgen levels in post-orchiectomy prostatic cancer patients

1 reference

12 December 2020

Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer

1 reference

12 December 2020

Hormonal therapy of prostatic cancer

1 reference

12 December 2020

Aromatase inhibition by R 76713: experimental and clinical pharmacology

1 reference

12 December 2020

Aminoglutethimide in tamoxifen-resistant patients: The Melbourne Experience

1 reference

12 December 2020

Adrenal steroid levels in castrated men with prostatic carcinoma treated with aminoglutethimide plus hydrocortisone.

1 reference

12 December 2020

Effects of aminoglutethimide on adrenal steroid secretion

1 reference

12 December 2020

The influence of a graded dose schedule of aminoglutethimide on the disposition of the optical enantiomers of warfarin in patients with breast cancer

1 reference

12 December 2020

The Effect of an Aromatase Inhibitor, 4-Hydroxy-4-Androstene- 3,17-Dione, On Estrogen-Dependent Processes in Reproduction and Breast Cancer11

1 reference

12 December 2020

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

12 December 2020

Biological determinants of altered pharmacokinetics in the elderly

1 reference

12 December 2020

Orchiectomy for advanced prostatic carcinoma A reevaluation

1 reference

12 December 2020

Phase II study of low dose aminoglutethimide 250 mg/day plus hydrocortisone in advanced postmenopausal breast cancer

1 reference

12 December 2020

Antiestrogenic treatment of advanced and recurrent carcinoma corporis uteri--a phase II study of toremifene

1 reference

12 December 2020

1 reference

12 December 2020

Adrenal Suppression with Aminoglutethimide. III. Comparison of Plasma Δ4- and Δ5-Steroids in Postmenopausal Women Treated for Breast Carcinoma*

1 reference

12 December 2020

The interconversion and aromatization of androgens by human adipose tissue

1 reference

12 December 2020

Cholestatic jaundice and aminoglutethimide

1 reference

12 December 2020

Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy

1 reference

12 December 2020

DHT Concentrations in Human Prostate Cancer Tissue*

1 reference

12 December 2020

Stroma of human benign prostatic hyperplasia: preferential tissue for androgen metabolism and oestrogen binding

1 reference

12 December 2020

Aminoglutethimide in the treatment of advanced postmenopausal breast cancer

1 reference

12 December 2020

Plasma testosterone: an accurate monitor of hormone treatment in prostatic cancer

1 reference

12 December 2020

Effect of treatment with 4-hydroxyandrostenedione on the peripheral conversion of androstenedione to estrone and in vitro tumor aromatase activity in postmenopausal women with breast cancer.

1 reference

12 December 2020

Inhibition of Peripheral Aromatization of Androstenedione to Estrone in Postmenopausal Women with Breast Cancer Using Δ1Testololactone*

1 reference

12 December 2020

Aminoglutethimide medical adrenalectomy for advanced prostatic carcinoma

1 reference

12 December 2020

Estrogen Receptor Status and the Clinical Response to a Combination of Aminoglutethimide and Cortisol in Advanced Breast Cancer

1 reference

12 December 2020

4-hydroxyandrostenedione--further clinical and extended endocrine observations

1 reference

12 December 2020

Aminoglutethimide and cholestasis

1 reference

12 December 2020

Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer

1 reference

12 December 2020

Endocrine effects of low dose aminoglutethimide as an aromatase inhibitor in the treatment of breast cancer

1 reference

12 December 2020

A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer

1 reference

12 December 2020

Aromatase inhibition and experimental antitumor activity of FCE 24304, MDL 18962 and SH 489

1 reference

12 December 2020

A randomized phase II trial of aminoglutethimide and hydrocortisone versus combined aminoglutethimide, hydrocortisone and fluoxymesterone in advanced breast cancer

1 reference

12 December 2020

Aminoglutethimide and warfarin. A new important drug interaction

1 reference

12 December 2020

Endocrine and Therapeutic Effects of Aminoglutethimide in Premenopausal Patients with Breast Cancer

1 reference

12 December 2020

10.2165/00002512-199202060-00008

Identifiers

DOI

1 reference

PubMed ID

1493356

Dimensions Publication ID

9 August 2017

0 references

1 reference

PubMed ID

1493356